TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Phase 2, Parallel Group, Rollover Study of AKR-501 in Patients With ChronicITP Who Completed 28 Days of Study Treatment in Protocol 501-CL-003

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients who completed 28 days of study treatment in Protocol 501-CL-003.~2. No significant safety or tolerability concerns from the patient's participation of Protocol 501-CL-003 as determined by the Investigator.~3. Received medical monitor approval for enrollment into this study.~4. Patients receiving maintenance corticosteroids may be enrolled, as long as the corticosteroids have been administered at a stable dose and the Investigator does not foresee the need to change the steroid dose during study participation. Patients should remain on this stable corticosteroid dose during study participation.~5. Women of child-bearing potential must have a negative serum pregnancy test at the Day 28 assessment in Protocol 501-CL-003. (Childbearing potential is defined as any woman who has not been surgically sterilized and is pre-menopausal or peri-menopausal i.e., any menstrual flow within 12 months of Screening Visit A for Protocol 501-CL-003).~6. Women of child-bearing potential must agree to practice a medically approved form of contraception (one of the following must be used: condoms (male or female) with a spermicidal agent, diaphragm or cervical cap with a spermicidal agent, IUD,hormonal contraception, abstinence).~7. Willing and able to provide written informed consent.~Exclusion Criteria:~1. Women who are pregnant and/or lactating.~2. Use of the following drugs or treatments:~   * Rituximab~  * Azathioprine, Cyclosporine A, or other immunosuppressant therapy~  * Aspirin, Aspirin-containing compounds, Salicylates,Anticoagulants, Non-steroidal anti-inflammatory drugs(NSAIDs)(including Cyclooxygenase-2 \[COX-2\] specific NSAIDs), clopidogrel; ticlopidine; and any drugs that affect platelet function.~  * Danazol~  * Rh0(D) immune globulin (WinRho®) or intravenous immunoglobulin (IVIG).~3. Inability to comply with protocol requirements or give informed consent, as determined by the Investigator.~For more information regarding inclusion/exclusion criteria, please see record for AKR 501-CL-003 Protocol.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (double-blind) (Type: EXPERIMENTAL): None
- Avatrombopag tablets (open-label) (Type: EXPERIMENTAL): None
- Avatrombopag tablets (double-blind) (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of SPARC1310 in Seasonal Allergic Rhinitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female participants aged 18 to 65 years with history of seasonal allergic rhinitis~* Participants able to understand and willing to sign the informed consent form~Exclusion Criteria:~* Anotomical deviations of the nasal septum that significantly impair ventilation or airflow~* Pregnant or nursing women~* Positive serology for infectious disease (Hepatitis B or C, HIV) at screening~* Parallel participation in another current investigational study, participation in a study within less than 30 days prior to study entry, or previous participation in this same study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- SPARC Placebo (Type: PLACEBO_COMPARATOR): None
- SPARC1310 I (Type: EXPERIMENTAL): None
- SPARC1310 II (Type: EXPERIMENTAL): None
- SPARC1310 III (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Intraluminal Therapy for Helicobacter Pylori Infection

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients aged greater than 20 years and less than 75 years~2. Patients have H. pylori infection without prior eradication therapy~3. Patients are willing to receive the intraluminal therapy. The written informed consents will be obtained from all patients prior to enrollment.~Exclusion Criteria:~1. Children and teenagers aged less than 20 years, and adult greater than 75 years~2. Contraindication for endoscopic examination or food retention in the gastric lumen.~3. History of gastrectomy; Gastroduodenal stenosis、deformity or obstruction; Gastroduodenal malignancy, including adenocarcinoma and lymphoma~4. Contraindication to treatment drugs: previous allergic reaction to antibiotics (amoxicillin, clarithromycin, metronidazole), Proton pump inhibitors (lansoprazole), Acetylcystein and Sucralfate; pregnant or lactating women~5. Severe concurrent acute or chronic illness: renal failure, cirrhosis of liver, incurable malignant disease~6. Patients who cannot give informed consent by himself or herself.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Group A (Drug: 7-day triple therapy) (Type: ACTIVE_COMPARATOR): Intervention : Drug: 7-day triple therapy. Patients fail to achieve intraluminal eradication of H. pylori will be randomly assigned to the oral antibiotics rescue therapies with standard 7-day triple therapy ( lansoprazole 30 mg b.i.d., amoxicillin 1 g b.i.d. and clarithromycin 500 mg b.i.d. for 7 days)
- Group B (Drug: 14-day triple therapy) (Type: SHAM_COMPARATOR): Intervention : Drug: 14-day triple therapy. Patients fail to achieve intraluminal eradication of H. pylori will be randomly assigned to the oral antibiotics rescue therapies with standard 14-day triple therapy ( lansoprazole 30 mg b.i.d., amoxicillin 1 g b.i.d. and clarithromycin 500 mg b.i.d. for 14 days).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Non-US Study of AA4500 (XIAFLEX™, Proposed Name) in the Treatment of Advanced Dupuytren's Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects with a diagnosis of advanced Dupuytren's disease, with a fixed flexion deformity of at least one finger, other than the thumb, that had a contracture at least 20°, but not greater than 100°, for MP (80° for PIP) joints, caused by a palpable cord.~* Had a positive table top test, defined as the inability to simultaneously place the affected finger(s) and palm flat against a table top.~* Were naive to AA4500 treatment~* Were judged to be in good health, based upon the results of a medical history, physical examination, and safety laboratory profile.~Exclusion Criteria:~* Had a chronic muscular, neurological, or neuromuscular disorder that affected the hands.~* Had received a treatment for advanced Dupuytren's disease, including surgery (fasciectomy or surgical fasciotomy), needle aponeurotomy/fasciotomy, or injection of verapamil and/or interferon on the selected primary joint within 90 days before the first dose of study drug.~* Had a known recent history of stroke, bleeding, a disease process that affected the hands, or other medical condition, which in the investigator's opinion, would make the subject unsuitable for enrollment in the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- AA4500 0.58 mg (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Propofol for Supreme LMA Insertion With and Without Remifentanil

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* ASA II-II patients Scheduled to ambulatory surgery Need of general anaesthesia General anaesthesia usually performed with laryngeal mask Negative pregnancy test in women. Signed informed consent.~Exclusion Criteria:~* Patients with a potentially difficult airway o (Mallampati III or IV, a limited mouth opening and/or cervical spine disease) Patients with reactive airway disease Signs of upper respiratory infection, Patients who had a risk of gastric aspiration

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- propofol (Type: ACTIVE_COMPARATOR): In control group, propofol concentrations will start at 4 μg ml-1, with 0,5 μg ml-1 as the step size, with the coadministration of saline.
- propofol and remifentanil (Type: EXPERIMENTAL): In propofol-remifentanil group, propofol + remifentanil at a target-controlled infusion 5 ng/mL will be coadministered.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: MSB11022 in Healthy Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy male subjects and healthy female subjects of non-childbearing potential aged 18 to 55 years, inclusive.~* Other protocol defined inclusion criteria could apply.~Exclusion Criteria:~* Concurrent or history infections such as opportunistic infections, including sepsis, pneumonia, and fungal infection.~* Individuals with history of tuberculosis or diagnosed with tuberculosis by interview, chest X-ray examination, or interferon-gamma release assay.~* Concurrent or history of demyelinating disease (multiple sclerosis, etc.).~* Concurrent or history of congestive cardiac failure.~* Concurrent or history of allergic symptoms such as asthma bronchial, drug-induced rash, and urticaria, which, in the judgment of the investigator, may affect participation in this clinical study.~* Concurrent or history of cardiac, hepatic, renal, gastrointestinal, respiratory, and/or hematological function disorders, which, in the judgment of the investigator or any of the sub investigators, may affect participation in this clinical study.~* Other protocol defined exclusion criteria could apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- MSB11022 (Type: EXPERIMENTAL): None
- US-licensed Humira (Type: ACTIVE_COMPARATOR): None
- EU-approved Humira (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Subject or legal representative must understand the investigational nature of this study and sign an Independent Ethics Committee/Institutional Review Board approved written informed consent form prior to receiving any study related procedure~* Outpatients with histologically/cytologically documented or radiographically diagnosed unresectable hepatocellular carcinoma (HCC) who are candidates for systemic therapy and for whom a decision to treat with sorafenib has been made; radiographic diagnosis needs typical findings of HCC by a radiographic method, i.e. on multi-dimensional dynamic computed tomography (CT), CT hepatic arteriography (CTHA)/CT arterial portography (CTAP) or magnetic resonance imaging (MRI)~* Patients must have a life expectancy of at least 8 weeks~* Patients must not have any evidence of bleeding diathesis or active gastrointestinal bleeding~Exclusion Criteria:~* Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements~* Pregnant or nursing female subjects~* Unwilling or unable to follow protocol requirements~* Any condition which in the investigator's opinion deems the subject an unsuitable candidate to receive study drug~* Patients who have had prior anti-angiogenic therapy, including but not limited to sorafenib, brivanib, bevacizumab, or sunitinib; prior treatment with liver directed, ablative or surgical therapies will be permitted as long as there is documented progression justifying the need for starting sorafenib therapy~* No known contraindications to anti-angiogenics such as severe coronary artery disease, recent myocardial infarction or stroke within 6 months, bleeding peptic ulcer or varices within last 3 months, and any other major illness that may jeopardize study treatment or follow up

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment (sorafenib tosylate) (Type: EXPERIMENTAL): Patients receive sorafenib tosylate PO BID. Treatment continues in the absence of disease progression or unacceptable toxicity.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of the Large Diameter GORE EXCLUDER® AAA Endoprosthesis in Abdominal Aneurysms

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Infrarenal AAA \> or equal to 4.5 cm in diameter~* Proximal infrarenal aortic neck length \> or equal 15mm~* Anatomy meets 31mm EXCLUDER specification criteria~* Access vessel able to receive 20 Fr. introducer sheath~* Life expectancy \>2 years~* Surgical candidate~* ASA Class I, II, III, or IV~* NYHA Class I, II, III~* 21 years of age or older~* Male or infertile female~* Ability to comply with protocol requirements including follow-up~* Signed Informed Consent Form~Exclusion Criteria:~* Mycotic or ruptured aneurysm~* Participating in another investigational device or drug study within 1 year~* Documented history of drug abuse within 6 months~* Coexisting thoracic aortic aneurysm (50% larger than proximal aorta)~* Myocardial infarction or cerebral vascular accident within 6 weeks~* Pulmonary insufficiency requiring chronic home oxygen therapy or inability to ambulate due to pulmonary function~* Renal insufficiency (Creatinine \> 2.5 mg/dL) without dialysis~* Iliac anatomy that would require occlusion of both internal iliac arteries~* Planned occlusion or reimplantation of significant mesenteric or renal arteries~* Planned concomitant surgical procedure or previous major surgery within 30 days~* Previous prosthesis placement in the same position of the aorta or iliac arteries~* Degenerative connective tissue disease, e.g., Marfans and Ehlers Danlos Syndrome~* Proximal neck angulation \> 60 degrees~* Presence of significant thrombus at arterial implantation sites

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 31 mm GORE EXCLUDER® Test Subjects (Type: EXPERIMENTAL): GORE EXCLUDER® AAA Endoprosthesis - 31 mm device implanted for the primary treatment of infrarenal abdominal aortic aneurysms (AAA)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Sofosbuvir/Velpatasvir ± Ribavirin for 12 Weeks in Adults With Chronic HCV Infection and Decompensated Cirrhosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~* Chronic HCV-infected males and non-pregnant/non-lactating females~* Treatment naive or treatment experienced individuals~* Child-Pugh-Turcotte Score 7-12 at screening~Note: Other protocol defined Inclusion/Exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- SOF/VEL (Type: EXPERIMENTAL): SOF/VEL for 12 weeks
- SOF/VEL + RBV (Type: EXPERIMENTAL): SOF/VEL + RBV for 12 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Metformin in Co-morbid Diabetes or Prediabetes and Serious Mental Illness

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients within 5 years of diagnosis of schizophrenia, schizoaffective disorder , or bipolar disorder(DSM V), or those younger than 40 years old, regardless of duration of illness~* Co-morbid diagnosis of prediabetes or diabetes (Canadian or American Diabetes Association criteria)~Exclusion Criteria:~* Patients with co-morbid axis, other than nicotine dependence, or cannabis abuse~* Patients with liver, or renal dysfunction,~* Patients with a positive drug urine screen (other than cannabis or nicotine)~* Females with a positive pregnancy test will be excluded.~* Prior trial with metformin, and reported lack of tolerability~* Patients with an A1C \> 9.5%, or symptomatic hyperglycemia with metabolic decompensation

- Gender: ALL
- Minimum Age: 17 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- Metformin (Type: PLACEBO_COMPARATOR): Metformin/ placebo will be dispensed on a biweekly basis, and pill counts conducted at each visit.
- Placebo (Type: PLACEBO_COMPARATOR): Metformin/ placebo will be dispensed on a biweekly basis, and pill counts conducted at each visit.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Test the Safety of the Investigational Drug Larotrectinib in Adults That May Treat Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 7.0

Eligibility Criteria:
Inclusion Criteria:~* Adult patients with a locally advanced or metastatic solid tumor that has progressed or was nonresponsive to available therapies, are unfit for standard chemotherapy or for which no standard or available curative therapy exists~* Proof of a malignancy harboring a NTRK fusion~* Eastern Cooperative Oncology Group (ECOG) score of 0, 1 or 2 and a life expectancy of at least 3 months~* Adequate hematologic, hepatic, and renal function~Exclusion Criteria:~* Patients with unstable primary central-nervous-system tumors or metastasis, exceptions possible~* Clinically significant active cardiovascular disease or history of myocardial infarction~* Active uncontrolled systemic bacterial, viral, or fungal infection~* Current treatment with a strong CYP3A4 inhibitor or inducer~* Pregnancy or lactation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Tumor patients_Dose 1 (Type: EXPERIMENTAL): Adult patients with solid tumors receiving 50 mg of BAY2757556 once daily (dose escalation cohort).
- Tumor patients_Dose 2 (Type: EXPERIMENTAL): Adult patients with solid tumors receiving 100 mg of BAY2757556 once daily (dose escalation cohort).
- Tumor patients_Dose 3 (Type: EXPERIMENTAL): Adult patients with solid tumors receiving 100 mg of BAY2757556 twice daily (dose escalation cohort).
- Tumor patients_Dose 4 (Type: EXPERIMENTAL): Adult patients with solid tumors receiving 200 mg of BAY2757556 once daily (dose escalation cohort).
- Tumor patients_Dose 5 (Type: EXPERIMENTAL): Adult patients with solid tumors receiving 150 mg of BAY2757556 twice daily (dose escalation cohort).
- Tumor patients_Dose 6 (Type: EXPERIMENTAL): Adult patients with solid tumors receiving 200 mg of BAY2757556 twice daily (dose escalation cohort).
- Tumor patients_Expansion (Type: EXPERIMENTAL): Adults patients with solid tumors and neurotrophic tyrosine kinase (NTRK) genes or proteins of types 1 - 3 (dose expansion cohort).~Patients receive either the recommended or maximum tolerated dose of BAY2757556 as determined in the dose escalation part.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete